Abstract
Pancreatic cancer (PC) is the seventh most common cause of death with a poor prognosis. Although there are many advanced therapeutic approaches, the 5-year survival rate of PC is approximately 11%, so it is one of the most aggressive cancers. The absence of potential biomarkers for early detection and screening is the main reason for poor prognosis and chemoresistance. Personalized medicine (PM) is an emerging approach using the characteristics and differences of patients in the molecular, physiological, environmental, and behavioral fields for better decision-making. In addition, novel quantitative imaging methods, including radiomic and deep learning, make a new noninvasive PM for a better early diagnosis and treatment of PC. However, PM encounters challenges that should be addressed that slow down its worldwide development, including ethical issues and relatively high costs. Here we summarize the novel therapeutic approaches and emerging research models, including patient derived xenograft (PDX) and 3-dimensional organoids, based on the patient’s tumor profile, which provides a better understanding of tumor and TME behavior and its response to drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Recent Advances in Nanocarriers for Pancreatic Cancer Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
